Latham steps into dispute over $6bn treatment, replacing Kirkland

Firm takes over Novartis in major patent litigation | Move follows rival firm's withdrawal after conflict-of-interest challenge | Latham team led by new hire from Cravath.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Biotech seeks to stop Kirkland from representing rival in Eylea dispute

19 June 2025 Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.

Americas

Court dismisses Regeneron’s antitrust countersuit against Novartis

3 February 2022 Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.

article

Regeneron convinces PTAB to review Novartis syringe patent

28 October 2021 The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

More features

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

EPO ruling clarifies appeal rights, blocking third-party intervention

Biotech sues AstraZeneca and Cellectis over mRNA patents

Latham steps into dispute over $6bn treatment, replacing Kirkland

More on this story

Editor's picks

Editor's picks

More features